Furthermore, the reduction in SMAD2/3 phosphorylation following treatment with HE and OE suggests that these compounds may exert their antifibrotic effects by interfering with the TGF-β/SMAD signaling pathway, thereby preventing the transcriptional activation of genes responsible for fibrotic matrix accumulation. The gene discussed is SMAD2; the disease is hereditary elliptocytosis.